|
Published limit for N-Nitroso-Vonoprazan
|
|
3
|
503
|
May 29, 2026
|
|
đŁ Theoretical and Experimental Assessment of Nitrosamine Risk in Industrial Solvent Recovery -Pub
|
|
3
|
490
|
May 29, 2026
|
|
Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products -Pub
|
|
4
|
384
|
May 27, 2026
|
|
Why EMA still assigns AI limits (CPCA) for nitrosamines in oncology drugs
|
|
7
|
445
|
May 27, 2026
|
|
Solution stability of NDSRI
|
|
8
|
387
|
May 25, 2026
|
|
Nitrite in Amines
|
|
15
|
972
|
May 21, 2026
|
|
N-Nitroso Perindopril Limit as NMI or 1500ng/day
|
|
3
|
251
|
May 21, 2026
|
|
Development and Validation of a Trace-Level LCâMS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
104
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2907
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
94
|
May 20, 2026
|
|
Liquid ChromatographyâHigh-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
79
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LCâHRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
125
|
May 20, 2026
|
|
N Nitroso Tadalfil
|
|
14
|
1145
|
May 20, 2026
|
|
đ°đˇ MFDS Guideline: Compilation of Analysis Methods on the Determination of Impurities in Pharmaceuticals, May-2026
|
|
2
|
291
|
May 19, 2026
|
|
Nitrosamine Workshop, Hyderabad, August 19 & 20
|
|
2
|
237
|
May 19, 2026
|
|
Source of N-nitroso-n-methylaniline (NMPA)
|
|
7
|
330
|
May 19, 2026
|
|
Regulatory Rationale for Restricting LTL Application to Nitrosamines
|
|
4
|
471
|
May 19, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1158
|
May 18, 2026
|
|
Science-led approaches to nitrosamine qualification and safety assessment-webinar
|
|
1
|
219
|
May 15, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
397
|
May 13, 2026
|
|
N-Nitroso Mefanaminc Acid
|
|
1
|
148
|
May 12, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
183
|
May 8, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
360
|
May 8, 2026
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
2
|
403
|
May 6, 2026
|
|
Generic Drugs Forum (GDF) 2026
|
|
17
|
880
|
May 5, 2026
|
|
Benchmark Dose (BMD) Modeling for Risk Assessment webinar
|
|
1
|
313
|
May 4, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of NâNitrosamines-Pub
|
|
2
|
174
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
507
|
April 30, 2026
|
|
Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice -Pub
|
|
5
|
470
|
April 30, 2026
|
|
N-Nitroso dially amine estimation by LCMS
|
|
2
|
93
|
April 29, 2026
|